Rui Kang Pharmaceutical Group Investments Limited announced that the Group is expected to record a loss for the three months ended 31 March 2016 for its continuing operations. Such loss was mainly due to the Group recorded a significant decrease in the net gain on financial assets at fair value through profit or loss for the three months ended 31 March 2015 amounted to approximately HKD 11.99 million; the continued difficult business environment in relation to the increased pressure on the selling price for certain products and the cost of sales for the manufacture of health related and pharmaceutical products segment and the higher fixed costs per testing for the newly set up molecular laboratory which commenced business in October 2015.